Abpro Holdings, Inc.
ABPOOTCHealthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | |
|---|---|---|---|---|---|
| Revenue | — | $183,000 | $122,000 | — | — |
| Operating income | −$8.5M | −$9.9M | −$11.7M | −$2.1M | −$1,793 |
| Net income | −$2.9M | −$7.2M | $2.8M | $886,918 | −$1,793 |
| Total assets | $1.1M | $4.7M | $3.4M | $310.6M | $361,372 |
| Total liabilities | — | $18.6M | $16.2M | $15.3M | $338,165 |
| Equity | −$8.8M | −$15.5M | −$89.0M | −$11.2M | $23,207 |
| EPS (diluted) | $-1.30 | $-22.31 | $-0.61 | — | — |
| Shares out. | 52.2M | 1.7M | 19.2M | 7.5M | — |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- 32.7%
- Return on assets
- −272.1%
- Return on capital (ROCE)
- —
- Liabilities / assets
- —
- Debt / equity
- —
- Book value / share
- $-0.17
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Accruals / assets
- 292.9%high accruals
- Piotroski F-Score
- 0/6weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 2 severe● 2 warning● 1 good- Negative shareholder equity
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Negative operating cash flow
- High accruals — earnings-quality risk
- Strong return on equity (>15%)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗May 15, 2026
- NT 10-Kmissed a reporting deadline ↗Mar 31, 2026
- NT 10-Kmissed a reporting deadline ↗Apr 1, 2025
- NT 10-Qmissed a reporting deadline ↗Nov 15, 2024
- NT 10-Qmissed a reporting deadline ↗Aug 14, 2024
- NT 10-Qmissed a reporting deadline ↗May 15, 2024
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Goldman Sachs Group IncPassive (13G)Feb 9, 2026
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 58,223 | 1.3 | -20.2% |
| Apr 30, 2026 | 72,921 | 1.6 | +8.3% |
| Apr 15, 2026 | 67,299 | 2.7 | -7.5% |
| Mar 31, 2026 | 72,773 | 2.2 | -12.2% |
| Mar 13, 2026 | 82,840 | 1.0 | -9.8% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Delisting / listing-standard noticeFeb 20, 2026
- Delisting / listing-standard notice · Director / officer changeFeb 11, 2026
- Director / officer changeFeb 3, 2026
- Entered a material agreement · New financial obligation · Director / officer changeJan 23, 2026
- Regulation FD disclosureJan 6, 2026
- Regulation FD disclosureDec 15, 2025
- Regulation FD disclosureDec 9, 2025
- Regulation FD disclosureNov 4, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 10-QQUARTERLY REPORTMay 20, 2026
- NT 10-QNOTIFICATION OF LATE FILINGMay 15, 2026
- 10-K/AAMENDMENT NO. 1 TO FORM 10-KMay 1, 2026
- 10-KANNUAL REPORTApr 15, 2026
- NT 10-KNOTIFICATION OF LATE FILINGMar 31, 2026
- 8-KCURRENT REPORTFeb 20, 2026
- 8-KCURRENT REPORTFeb 11, 2026
- SCHEDULE 13GFeb 9, 2026
- 8-KCURRENT REPORTFeb 3, 2026
- 8-KCURRENT REPORTJan 23, 2026
- 8-KCURRENT REPORTJan 6, 2026
- 8-KCURRENT REPORTDec 15, 2025
- 8-KCURRENT REPORTDec 9, 2025
- EFFECTDec 2, 2025
- CORRESPDec 2, 2025
Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.